113 related articles for article (PubMed ID: 18528189)
41. Antigranulocyte antibody bone marrow scans in cancer patients with metastatic bone superscan appearance.
Berná L; Torres G; Carrió I; Estorch M; Germá JR; Alonso C
Clin Nucl Med; 1994 Feb; 19(2):121-8. PubMed ID: 8187396
[TBL] [Abstract][Full Text] [Related]
42. Computer-aided quantitative bone scan assessment of prostate cancer treatment response.
Brown MS; Chu GH; Kim HJ; Allen-Auerbach M; Poon C; Bridges J; Vidovic A; Ramakrishna B; Ho J; Morris MJ; Larson SM; Scher HI; Goldin JG
Nucl Med Commun; 2012 Apr; 33(4):384-94. PubMed ID: 22367858
[TBL] [Abstract][Full Text] [Related]
43. Metastatic superscan on (99m)Tc-MDP bone scintigraphy in a case of carcinoma colon: Common finding but rare etiology.
Chakraborty PS; Sharma P; Karunanithi S; Bal C; Kumar R
Indian J Nucl Med; 2014 Jul; 29(3):158-9. PubMed ID: 25210281
[TBL] [Abstract][Full Text] [Related]
44. [Usefulness of spatially adaptive noise reduction processing in computer-assisted diagnosis system for bone scintigraphy].
Ichikawa H; Onoguchi M; Okuda K; Kato T; Terabe M; Shimada H
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2014 May; 70(5):461-6. PubMed ID: 24858291
[TBL] [Abstract][Full Text] [Related]
45. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease.
Pasoglou V; Michoux N; Peeters F; Larbi A; Tombal B; Selleslagh T; Omoumi P; Vande Berg BC; Lecouvet FE
Radiology; 2015 Apr; 275(1):155-66. PubMed ID: 25513855
[TBL] [Abstract][Full Text] [Related]
46. Development of Convolutional Neural Networks to identify bone metastasis for prostate cancer patients in bone scintigraphy.
Papandrianos N; Papageorgiou EI; Anagnostis A
Ann Nucl Med; 2020 Nov; 34(11):824-832. PubMed ID: 32839920
[TBL] [Abstract][Full Text] [Related]
47. Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination.
Roebuck JR; Haker SJ; Mitsouras D; Rybicki FJ; Tempany CM; Mulkern RV
Magn Reson Imaging; 2009 May; 27(4):497-502. PubMed ID: 18823731
[TBL] [Abstract][Full Text] [Related]
48. Scoring systems of quantitative bone scanning in prostate cancer: historical overview, current status and future perspectives.
Zafeirakis A
Hell J Nucl Med; 2014; 17(2):136-44. PubMed ID: 24997079
[TBL] [Abstract][Full Text] [Related]
49. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
[TBL] [Abstract][Full Text] [Related]
50. Observer agreement and accuracy in the evaluation of bone scans in newly diagnosed prostate cancer.
Zacho HD; Manresa JA; Mortensen JC; Bertelsen H; Petersen LJ
Nucl Med Commun; 2015 May; 36(5):445-51. PubMed ID: 25646705
[TBL] [Abstract][Full Text] [Related]
51. High and ultra-high b-value diffusion-weighted imaging in prostate cancer: a quantitative analysis.
Wetter A; Nensa F; Lipponer C; Guberina N; Olbricht T; Schenck M; Schlosser TW; Gratz M; Lauenstein TC
Acta Radiol; 2015 Aug; 56(8):1009-15. PubMed ID: 25168023
[TBL] [Abstract][Full Text] [Related]
52. [Radionuclide diagnosis and therapy of skeletal metastases of prostatic cancer].
Schümichen C
Radiologe; 1984 Jan; 24(1):13-8. PubMed ID: 6200897
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.
Franiel T; Lüdemann L; Rudolph B; Rehbein H; Staack A; Taupitz M; Prochnow D; Beyersdorff D
Invest Radiol; 2008 Jul; 43(7):481-7. PubMed ID: 18580330
[TBL] [Abstract][Full Text] [Related]
54. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
[TBL] [Abstract][Full Text] [Related]
55. A visual and semi-quantitative assessment of (99m)Tc-EDDA/HYNIC-TOC scintigraphy in differentiation of solitary pulmonary nodules.
Płachcińska A; Mikołajczak R; Kozak J; Rzeszutek K; Kuśmierek J
Nucl Med Rev Cent East Eur; 2004; 7(2):143-50. PubMed ID: 15968601
[TBL] [Abstract][Full Text] [Related]
56. Phantom studies and clinical application of high resolution, image reconstruction using (18)F-fluoromethylcholine PET/CT for prostate cancer.
Zielinski A; Behrendt FF; Verburg FA; Mottaghy FM; Krohn T
Hell J Nucl Med; 2014; 17(3):194-9. PubMed ID: 25397625
[TBL] [Abstract][Full Text] [Related]
57. Superscan in patients with nasopharyngeal carcinoma.
Liu RS; Chu YK; Chu LS; Yeh SH; Yen SH; Chen KY; Chen YK; Shen YY
Clin Nucl Med; 1996 Apr; 21(4):302-6. PubMed ID: 8925613
[TBL] [Abstract][Full Text] [Related]
58. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer.
Zanzonico PB; Finn R; Pentlow KS; Erdi Y; Beattie B; Akhurst T; Squire O; Morris M; Scher H; McCarthy T; Welch M; Larson SM; Humm JL
J Nucl Med; 2004 Nov; 45(11):1966-71. PubMed ID: 15534070
[TBL] [Abstract][Full Text] [Related]
59. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.
Nakamoto Y; Osman M; Wahl RL
Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709
[TBL] [Abstract][Full Text] [Related]
60. Clinical significance of metabolic superscan in patients with hyperthyroidism.
Kotb MH; El-Maghraby T; Khalafallah K; Omar W; Grace BD; Al-Nahhas A
Nucl Med Rev Cent East Eur; 2007; 10(2):76-81. PubMed ID: 18228210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
